1.19  0 (0%)		07-17 16:00
Open: 1.19 High: 1.22 Volume: 1,730,074		Pre. Close: 1.19 Low: 1.18 Market Cap: 899(M)

Short term
Mid term
Targets	6-month :	1.68	1-year :	1.88
Resists	First :	1.44	Second :	1.61
Pivot price	1.38
Supports	First :	1.17	Second :	0.97
MAs	MA(5) :	1.2	MA(20) :	1.4
	MA(100) :	1.25	MA(250) :	1.31
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	3	D(3) :	3.8
RSI	RSI(14): 25.5
52-week	High :	1.61	Low :	0.98

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ OPK ] has closed above bottom band by 14.3%. Bollinger Bands are 193.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.22 - 1.23	1.23 - 1.24
Low:	1.16 - 1.17	1.17 - 1.18
Close:	1.17 - 1.19	1.19 - 1.2

OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.

Wed, 15 Jul 2026
OPKO Health Inc (OPK) Institutional Confidence - TradingKey

Thu, 02 Jul 2026
OPKO Health (OPK) Piper Sandler 36th Annual Healthcare Conference Summary - Quartr

Thu, 25 Jun 2026
OPK Forecast — Price Target — Prediction for 2027 - TradingView

Mon, 22 Jun 2026
Director at OPKO (NASDAQ: OPK) receives grant of 60,000 stock options - Stock Titan

Mon, 22 Jun 2026
OPKO Health (OPK) director receives 30,000-share stock option award at $1.42 - Stock Titan

Thu, 28 May 2026
OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	755 (M)
Shares Float	333 (M)
Held by Insiders	49.9 (%)
Held by Institutions	27 (%)
Shares Short	32,590 (K)
Shares Short P.Month	33,040 (K)

EPS	-0.26
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.6
Profit Margin	-36.7 %
Operating Margin	-41.1 %
Return on Assets (ttm)	-6.4 %
Return on Equity (ttm)	-17 %
Qtrly Rev. Growth	-17.3 %
Gross Profit (p.s.)	0.11
Sales Per Share	0.76
EBITDA (p.s.)	-0.15
Qtrly Earnings Growth	0 %
Operating Cash Flow	-163 (M)
Levered Free Cash Flow	-36 (M)

PE Ratio	-4.58
PEG Ratio	93.6
Price to Book value	0.74
Price to Sales	1.54
Price to Cash Flow	-5.51

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.